This antibody targets LPLUNC1 (C20orf114), a protein naturally secreted in the airway, and is of the IgG1 isotype. It was developed using recombinant human LPLUNC1 as the immunogen and has been validated for several applications such as Western blot, ELISA, and immunostaining in human samples. The approach leverages in vitro studies to ascertain its potential for modulating respiratory infections by addressing a key component present in the natural airway defense system.
Description
What differentiates this technology is its focus on a naturally occurring protein in the respiratory tract, which distinguishes it from conventional methods. By targeting LPLUNC1, the technology offers a novel perspective on respiratory treatment strategies, potentially supplementing or replacing traditional antibiotic therapies. The specific design and validation process ensure high specificity and sensitivity, positioning this antibody as a promising candidate for diagnostic and therapeutic applications in respiratory medicine.
Applications
- Airway infection diagnostics
- Respiratory therapy development
- Immunoassay reagent production
Advantages
- Provides a targeted approach to modulate respiratory infections by focusing on the naturally secreted LPLUNC1 protein.
- Offers a versatile research tool validated for Western blot, ELISA, and immunostaining applications.
- Represents a potential alternative or complementary therapeutic modality to conventional antibiotics.
- Exhibits specificity to human samples, ensuring clinical relevance and translational potential.
IP Status
Research Tool
